Summary of use during lactation
Information in this record refers to the use of phosphorus P 32 as a therapeutic agent. No information is available on the use of phosphorus P 32 during breastfeeding. Use of phosphate P 32 as a skin patch to treat skin cancers poses no risk to breastfed infants after removal of the patch from the mother's skin
Drug levels in milk and infant serum
Phosphorus P 32 decays by beta emission with an energy of 1.709 MeV and a half-life of 14.3 days.[1]
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
References
- MountfordPJ WellsCP HallFM Potential radiation dose to a breast-fed infant following administration of sodium 32P-phosphate to the mother. Nucl Med Commun 1984 5 473 6 6531156 PubMed
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.